P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
TL;DR: Pomalidomide appears to be well tolerated; hematologic toxicities are the most commonly reported adverse events and peripheral neuropathy is rare; Phase III trials are currently underway to determine the optimal dose and combination regimen of pomalidOMide in the treatment of MM.
Journal ArticleDOI
Novel therapies in myeloma.
TL;DR: Thalidomide, lenalidomides and bortezomib can now be considered as standard options both as first-line agents and beyond for the treatment of myeloma, with respective combinations also emerging as valid choices for all stages of the disease.
Journal ArticleDOI
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials
David S. Siegel,Katja Weisel,Meletios A. Dimopoulos,Rachid Baz,Paul G. Richardson,Michel Delforge,Kevin W. Song,Jesús F. San Miguel,Philippe Moreau,Hartmut Goldschmidt,Michele Cavo,Sundar Jagannath,Xin Yu,Kevin Hong,Lars Sternas,Mohamed H. Zaki,Antonio Palumbo +16 more
TL;DR: It is demonstrated that POM’+ LoDEX is a safe and effective treatment for patients with moderate RI, and median overall response rate, progression-free survival, time to progression, and duration of response were not significantly different between RI subgroups.
Journal ArticleDOI
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
Paul G. Richardson,Craig C. Hofmeister,Noopur Raje,David S. Siegel,Sagar Lonial,Jacob P. Laubach,Yvonne A. Efebera,David H. Vesole,Ajay K. Nooka,Jacalyn Rosenblatt,Deborah Doss,M. Zaki,Amine Bensmaine,Jennifer Herring,Yan Li,Latisha Watkins,Min S. Chen,KC Anderson +17 more
TL;DR: Pomalidomide, bortezomib and LoDEX was well tolerated and effective in lenalidomides-refractory and bortzomib-exposed patients with RRMM.
Journal ArticleDOI
Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation.
Paul G. Richardson,Asher A. Chanan-Khan,Sagar Lonial,Amrita Krishman,Michael C. Carroll,G. F. Cropp,K. Kersey,M. Abitar,Robert Johnson,Alison L. Hannah,Kenneth C. Anderson +10 more
TL;DR: Treatment with T/BZ combination produces durable anti-MM activity in BZ-refractory pts and data support the use of the suspension formulation in myeloma trials.